Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.65 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
| ▸ | GPR52 | Q9Y2T5 | 4/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033143 | 0.85 | PIK3CD (0.65) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL4038493 | 0.85 | PIK3CD (0.67) | PIK3CDPIK3CGPIK3CAPIK3CBGPR52 | |
| SCHEMBL3143365 | 0.83 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL48835 | 0.82 | PIK3CD (0.81) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| SCHEMBL4201345 | 0.82 | PIK3CD (0.67) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| SCHEMBL48466 | 0.82 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| SCHEMBL3099207 | 0.80 | GPR52 (0.50) | PIK3CDPIK3CGPIK3CAPIK3CBGPR52 | |
| SCHEMBL48660 | 0.79 | PIK3CG (1.00) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| SCHEMBL3141883 | 0.77 | PIK3CD (0.41) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 | |
| SCHEMBL6550367 | 0.77 | PIK3CD (0.41) | PIK3CDPIK3CGPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | claimed |
| EP-2311818-B1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | NOVARTIS AG (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-7902375-B2 | Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| CN-1838953-B | Phosphatidylinositol 3-kinase (PI) for the treatment of inflammatory airway diseases3) Inhibitor 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives | NOVARTIS AG | 2011-02-02 | — | — | CN | disclosed |
| US-7799810-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20100120865-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| EP-1689391-B1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| EP-2029562-A1 | 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis Ag (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| WO-2008000421-A2 | THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007134827-A1 | 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| CN-1838953-A | Phosphatidylinositol 3-kinase (PI3) inhibitor 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives for the treatment of inflammatory airway diseases | NOVARTIS AG (CH) | 2006-09-27 | — | — | CN | disclosed |
| EP-1689391-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| WO-2005021519-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
| EP-1480962-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072557-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | PIK3CD 4/4885PIK3CG 8/4885PIK3CA 1/4885 |
| US-20100120865-A1 | Organic compounds | PIK3C3, PIK3R3, PIK3R4 | PIK3CD 10/4885PIK3CG 12/4885PIK3CA 5/4885 |
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | CNKSR1, CDK8, MAPK8 | PIK3CD 92/4885PIK3CG 98/4885PIK3CA 51/4885 |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | PI4KA, IP6K3, PHOSPHO1 | PIK3CD 26/4885PIK3CG 23/4885PIK3CA 16/4885 |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | PIK3CD 4/4885PIK3CG 8/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.